Search Filters
Advanced Search
SMC ID Date Medicine Submission Type Indication
SMC2893 13/04/2026 acalabrutinib (Calquence) Abbreviated

In combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
SMC2543 11/09/2023 ibrutinib (Imbruvica) Full

In combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
SMC2509 07/11/2022 venetoclax (Venclyxto®) Non submission

In combination with low-dose cytarabine for the treatment of adult patients with newly-diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.
SMC2427 09/05/2022 venetoclax (Venclyxto) Full

In combination with obinutuzumab (VenG) is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
SMC2412 11/04/2022 venetoclax (Venclyxto) Full

In combination with a hypomethylating agent (HMA) for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy (IC).
SMC2293 07/12/2020 venetoclax (Venclyxto) Full

In combination with obinutuzumab (VenG) is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
SMC2166 12/08/2019 venetoclax (Venclyxto) Full

In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.
1249/17 07/08/2017 venetoclax (Venclyxto) Full as monotherapy for the treatment of chronic lymphocytic leukaemia (CLL): in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor. in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.

No medicines have been found.